RS62466B1 - Farmaceutske kompozicije koje sadrže doravirin, tenofovir dizoproksil fumarat i lamivudin - Google Patents
Farmaceutske kompozicije koje sadrže doravirin, tenofovir dizoproksil fumarat i lamivudinInfo
- Publication number
- RS62466B1 RS62466B1 RS20211287A RSP20211287A RS62466B1 RS 62466 B1 RS62466 B1 RS 62466B1 RS 20211287 A RS20211287 A RS 20211287A RS P20211287 A RSP20211287 A RS P20211287A RS 62466 B1 RS62466 B1 RS 62466B1
- Authority
- RS
- Serbia
- Prior art keywords
- doravirine
- lamivudine
- pharmaceutical compositions
- compositions containing
- tenofovir disoproxil
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562261953P | 2015-12-02 | 2015-12-02 | |
PCT/US2016/063894 WO2017095761A1 (en) | 2015-12-02 | 2016-11-29 | Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine |
EP16871332.9A EP3383397B1 (en) | 2015-12-02 | 2016-11-29 | Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine |
Publications (1)
Publication Number | Publication Date |
---|---|
RS62466B1 true RS62466B1 (sr) | 2021-11-30 |
Family
ID=58797976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20211287A RS62466B1 (sr) | 2015-12-02 | 2016-11-29 | Farmaceutske kompozicije koje sadrže doravirin, tenofovir dizoproksil fumarat i lamivudin |
Country Status (21)
Country | Link |
---|---|
US (2) | US10603282B2 (sr) |
EP (3) | EP4424373A2 (sr) |
JP (1) | JP6866374B2 (sr) |
KR (1) | KR20180081082A (sr) |
CN (1) | CN108367008B (sr) |
AU (1) | AU2016361612B2 (sr) |
BR (1) | BR112018011085B1 (sr) |
CA (1) | CA3006192C (sr) |
CY (1) | CY1124748T1 (sr) |
DK (1) | DK3383397T3 (sr) |
ES (1) | ES2895951T3 (sr) |
HR (1) | HRP20211687T1 (sr) |
HU (1) | HUE056978T2 (sr) |
LT (1) | LT3383397T (sr) |
MX (1) | MX2018006773A (sr) |
PL (1) | PL3383397T3 (sr) |
PT (1) | PT3383397T (sr) |
RS (1) | RS62466B1 (sr) |
RU (1) | RU2736941C2 (sr) |
SI (1) | SI3383397T1 (sr) |
WO (1) | WO2017095761A1 (sr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HRP20211687T1 (hr) * | 2015-12-02 | 2022-03-04 | Merck Sharp & Dohme Corp. | Farmaceutske kompozicije koje sadrže doravirin, tenofovir dizoproksil fumarat i lamivudin |
CA3060222A1 (en) * | 2017-04-18 | 2018-10-25 | Cipla Limited | Combination therapy for use in treating retroviral infections |
HRP20230645T1 (hr) * | 2018-02-02 | 2023-09-29 | Genentech, Inc. | Farmaceutski spoj, njegove soli, njegove formulacije i postupci izrade i upotrebe istih |
CN113288905A (zh) * | 2021-07-14 | 2021-08-24 | 石家庄龙泽制药股份有限公司 | 含多替拉韦钠、拉米夫定和富马酸诺福韦酯的药物组合物 |
CN115554248B (zh) * | 2022-08-25 | 2023-09-22 | 平阳润德医院有限公司 | 一种治疗小儿巨细胞病毒感染性肝炎的肠溶型中药制剂及其制备方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5047407A (en) | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
JP5231242B2 (ja) * | 2005-12-14 | 2013-07-10 | シプラ・リミテッド | ヌクレオチド及びヌクレオシド系逆転写酵素阻害剤(テノホビル及びラミブジン)を剤形の異なる部分に含む医薬組合せ |
US20090036357A1 (en) * | 2007-06-12 | 2009-02-05 | Concert Pharmaceuticals, Inc. | Azapeptide derivatives |
WO2009106960A2 (en) * | 2008-02-27 | 2009-09-03 | Aurobindo Pharma Limited | Stable compositions of lamivudine, tenofovir and efavirenz |
EP2295038B1 (en) * | 2009-09-11 | 2013-05-29 | AiCuris GmbH & Co. KG | Solid dispersion comprising an anti-HIV agent |
PT2924034T (pt) | 2010-03-30 | 2017-01-06 | Merck Canada Inc | Composição farmacêutica compreendendo um inibidor de transcritase reversa não nucleosídico |
US20140193491A1 (en) * | 2011-05-30 | 2014-07-10 | Cipla Limited | Pharmaceutical antiretroviral composition |
WO2014130553A2 (en) * | 2013-02-20 | 2014-08-28 | Abbvie Inc. | Tablet dosage forms |
WO2015077273A1 (en) | 2013-11-22 | 2015-05-28 | Merck Sharp & Dohme Corp. | Composition of a non-nucleoside reverse transcriptase inhibitor |
WO2015179448A1 (en) * | 2014-05-21 | 2015-11-26 | Gilead Sciences, Inc. | Therapeutic compounds |
HRP20211687T1 (hr) * | 2015-12-02 | 2022-03-04 | Merck Sharp & Dohme Corp. | Farmaceutske kompozicije koje sadrže doravirin, tenofovir dizoproksil fumarat i lamivudin |
-
2016
- 2016-11-29 HR HRP20211687TT patent/HRP20211687T1/hr unknown
- 2016-11-29 JP JP2018528299A patent/JP6866374B2/ja active Active
- 2016-11-29 CA CA3006192A patent/CA3006192C/en active Active
- 2016-11-29 MX MX2018006773A patent/MX2018006773A/es active IP Right Grant
- 2016-11-29 SI SI201631373T patent/SI3383397T1/sl unknown
- 2016-11-29 AU AU2016361612A patent/AU2016361612B2/en active Active
- 2016-11-29 PT PT168713329T patent/PT3383397T/pt unknown
- 2016-11-29 BR BR112018011085-0A patent/BR112018011085B1/pt active IP Right Grant
- 2016-11-29 PL PL16871332T patent/PL3383397T3/pl unknown
- 2016-11-29 DK DK16871332.9T patent/DK3383397T3/da active
- 2016-11-29 EP EP24183101.5A patent/EP4424373A2/en active Pending
- 2016-11-29 RU RU2018123620A patent/RU2736941C2/ru active
- 2016-11-29 ES ES16871332T patent/ES2895951T3/es active Active
- 2016-11-29 KR KR1020187015257A patent/KR20180081082A/ko not_active Application Discontinuation
- 2016-11-29 WO PCT/US2016/063894 patent/WO2017095761A1/en active Application Filing
- 2016-11-29 CN CN201680070227.0A patent/CN108367008B/zh active Active
- 2016-11-29 RS RS20211287A patent/RS62466B1/sr unknown
- 2016-11-29 EP EP21197509.9A patent/EP3960163A1/en active Pending
- 2016-11-29 EP EP16871332.9A patent/EP3383397B1/en active Active
- 2016-11-29 US US15/780,142 patent/US10603282B2/en active Active
- 2016-11-29 HU HUE16871332A patent/HUE056978T2/hu unknown
- 2016-11-29 LT LTEPPCT/US2016/063894T patent/LT3383397T/lt unknown
-
2020
- 2020-02-14 US US16/791,398 patent/US10842751B2/en active Active
-
2021
- 2021-11-19 CY CY20211101008T patent/CY1124748T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL265360B (en) | Pharmaceutical composition | |
HK1248547A1 (zh) | 包含替諾福韋和恩曲他濱的藥物製劑 | |
IL265260B (en) | pharmaceutical preparations | |
HK1254343A1 (zh) | 藥物製劑 | |
IL262654A (en) | Pharmacy preparation | |
ZA201903101B (en) | Pharmaceutical formulations | |
HUE056978T2 (hu) | Doravirint, tenofovir-dizoproxil-fumarátot és lamivudint tartalmazó gyógyszerészeti kompozíciók | |
IL265349A (en) | Pharmaceutical composition | |
PL3278801T3 (pl) | Kompozycja farmaceutyczna zawierająca mirabegron | |
IL263040A (en) | Pharmaceutical composition comprising eteplirsen | |
GB201615917D0 (en) | Pharmaceutical composition | |
HUE044889T2 (hu) | Gyógyászati készítmények | |
PL3454838T3 (pl) | Kompozycja farmaceutyczna | |
GB201615914D0 (en) | Pharmaceutical composition | |
GB201615910D0 (en) | Pharmaceutical composition | |
IL265436B (en) | Pharmacy preparation | |
HUE057830T2 (hu) | Famitinib tartalmú gyógyszerkészítmény | |
GB201620519D0 (en) | Pharmaceutical composition | |
IL265428A (en) | Pharmaceutical composition | |
PT3476391T (pt) | Composição farmacêutica que compreende arginina para utilização no tratamento da doença de poliq | |
GB201620513D0 (en) | Pharmaceutical composition | |
GB201620515D0 (en) | Pharmaceutical composition | |
GB201620516D0 (en) | Pharmaceutical composition | |
GB201620517D0 (en) | Pharmaceutical composition | |
GB201616093D0 (en) | Pharmaceutical composition |